Insulin resistance: from the source of development to clinical consequences
DOI:
https://doi.org/10.12775/JEHS.2020.10.07.015Keywords
insulin resistance, type 2 diabetes, polycystic ovary syndromeAbstract
Insulin resistance is a disorder of glucose homeostasis, which is a decrease in tissue sensitivity to insulin despite normal or elevated serum hormone levels. The main sources of development are genetic and environmental factors, including excessive consumption of fats, simple sugars and high-calorie foods, and lack of physical activity. One of the most objective methods of assessing insulin resistance is the HOMA-IR index calculated on the basis of glucose and insulin levels in the blood. Among the clinical consequences, type 2 diabetes and polycystic ovary syndrome play the most important role. The goal of treatment is not only to reduce insulin resistance, but also to protect pancreatic β cells.
References
Grzesiuk W, Szydlarska D, Jóźwik K. Insulinooporność w endokrynopatiach. Endokrynol. Otyłość i Zaburzenia Przemiany Mater. 2008;4:38–44.
Drzycimska-Tatka B, Drab-Rybczyńska A, Kasprzak J. Zespół metaboliczny-epidemia XXI wieku. Hygeia Public Heal. 2011;46:423–30.
Matulewicz N, Karczewska-Kupczewska M. Insulinooporność a przewlekła reakcja zapalna. Postep. Hig Med Dosw. 2016;70:1245–57.
Wesołowski P, Wańkowicz Z. Insulinooporność—metody rozpoznawania i następstwa kliniczne. Forum Nefrol. 2011;4:313–9.
Jasik M, Karnafel W. Pathophysiological aspects of insulin for the cardiovascular system and blood pressure values. Prz. Kardiodiabetologinczny. 2009;4:25–9.
Wilczak J, Jank M. Fizjologiczne I Biochemiczne Mechanizmy Związane Z Przemianami Energetycznymi Zachodzącymi W Czasie Wysiłku Fizycznego. Kosmos. 2010;4:403–11.
Luiza Napiórkowska EFF. Insulin resistance and prediabetes. Postępy Nauk Med. 2017.
Bednarek-Tupikowska G, Matczak-Giemza M, Kubicka E, Krzyżanowska-świniarska B. Metaboliczna otyłość u osób z prawidłową masą ciała. Endokrynol. Otyłość i Zaburzenia Przemiany Mater. 2007;3:55–61.
Barbara Dżygadło, Celina Łepecka-Klusek BP. Wykorzystanie analizy impedancji bioelektrycznej w profilaktyce i leczeniu nadwagi i otyłości Use of bioelectrical impedance analysis in prevention and treatment of overweight and obesity. Probl Hig Epidemiol. 2012;93:274–80.
Kokot IMM, Pawlik-Sobecka L, Płaczkowska S, Żółcińska-Wilczyńska M, Piwowar A. The relationship between total body fat and distribution of body fat mass and markers of insulin resistance in young women with normal weight — a pilot study. Clin. Diabetol. 2016;5:41–8.
Yaribeygi H, Farrokhi FRR, Butler AEE, Sahebkar A. Insulin resistance: Review of the underlying molecular mechanisms. J. Cell. Physiol. 2019;234:8152–61.
Gierach M, Gierach J, Junik R. Insulinooporność a choroby tarczycy. Endokrynol. Pol. 2014;65:70–6.
Słoma M, Szeja N. Wpływ antocyjanów na insulinooporność. Forum Zaburzeń Metab. 2018;9:175–81.
Stąpor N, Beń-Skowronek I. Insulin resistance in children. Pediatr. Endocrinol. Diabetes Metab. 2014;20:107–15.
Gutch M, Kumar S, Razi SMM, Gupta KKK, Gupta A. Assessment of insulin sensitivity/resistance. Indian J. Endocrinol. Metab. 2015;19:160–4.
Altuve M, Severeyn E, Wong S. Optimized fasting and OGTT-based simple surrogate methods for assessing insulin sensitivity. Diabetes Metab. Syndr. Clin. Res. Rev. 2019;13:2683–7.
Roden M, Petersen K, Shulman G. Insulin Resistance in Type 2 Diabetes. Textb. Diabetes. Chichester, UK: John Wiley & Sons, Ltd. 2016:174–86.
Polak K, Czyzyk · A, Simoncini · T, Meczekalski · B. New markers of insulin resistance in polycystic ovary syndrome. J Endocrinol Invest. 2017;40:1–8.
Ormazabal V, Nair S, Elfeky O, Aguayo C, Salomon C, Zuñiga FA. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc. Diabetol. 2018;17:1–14.
Warram JHH, Martin BCC, Krolewski ASS, Soeldner JSS, Kahn CRR. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann. Intern. Med. 1990;113:909–15.
Hanley AJGJG, Williams K, Gonzalez C, D’Agostino RBB, Wagenknecht LEE, Stern MPP et al. Prediction of type 2 diabetes using simple measures of insulin resistance: Combined results from the San Antonio Heart Study, the Mexico City Diabetes Study, and the Insulin Resistance Atherosclerosis Study. Diabetes. 2003;52:463–9.
Goedeke L, Perry RJ, Shulman GI. Emerging Pharmacological Targets for the Treatment of Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Type 2 Diabetes. Annu. Rev. Pharmacol. Toxicol. 2019;59:65–87.
Małecki MTT. Otyłość – insulinooporność – cukrzyca typu 2. Kardiol. Pol. 2006;64:561–6.
LeRoith D. β-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. Am. J. Med. 2002;113:3–11.
Lillioja S, Mott DMM, Spraul M, Ferraro R, Foley JEE, Ravussin E et al. Insulin Resistance and Insulin Secretory Dysfunction as Precursors of Non-Insulin-Dependent Diabetes Mellitus: Prospective Studies of Pima Indians. N. Engl. J. Med. 1993;329:1988–92.
Clark A, Jones LCC, De Koning E, Hansen BCC, Matthews DRR. Decreased insulin secretion in type 2 diabetes: A problem of cellular mass or function? Diabetes. American Diabetes Association. 2001;50:S169.
Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in poly cystic ovarian disease. J. Clin. Endocrinol. Metab. 1980;50:113–6.
Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38:1165–74.
Dunaif A. Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis*. Endocr. Rev. 1997;18:774–800.
Zeng B, Lai Z, Sun L, Zhang Z, Yang J, Li Z et al. Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study. Res. Microbiol. 2019;170:43–52.
Cheatham B, Kahn CR. Insulin action and the insulin signaling network. Endocr. Rev. 1995;16:117–42.
Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes. 1992;41:1257–66.
Seow K-M, Juan C-C, Hsu Y-P, Hwang J-L, Huang L-W, Ho L-T. Amelioration of insulin resistance in women with PCOS via reduced insulin receptor substrate-1 Ser312 phosphorylation following laparoscopic ovarian electrocautery. Hum. Reprod. 2007;22:1003–10.
Zafar U, Khaliq S, Ahmad HU, Manzoor S, Lone KP. Metabolic syndrome: an update on diagnostic criteria, pathogenesis, and genetic links. Hormones. 2018;17:299–313.
Wożakowska-Kapłon B. Nowe możliwości terapii osób z zespołem metabolicznym. Folia Cardiol. 2019;14:264–71.
Tankó LB, Siddiq A, Lecoeur C, Larsen PJ, Christiansen C, Walley A et al. ACDC/adiponectin and PPAR-γ gene polymorphisms: Implications for features of obesity. Obes. Res. 2005;13:2113–21.
Ginsberg HN. Insulin resistance and cardiovascular disease. J. Clin. Invest. 2000;106:453–8.
Bloomgarden ZT. Insulin Resistance, Dyslipidemia, and Cardiovascular Disease. Diabetes Care. 2007;30:2164–70.
Kong C, Elatrozy T, Anyaoku V, Robinson S, Richmond W, Elkeles RS. Insulin resistance, cardiovascular risk factors and ultrasonically measured early arterial disease in normotensive Type 2 diabetic subjects. Diabetes. Metab. Res. Rev. 2000;16:448–53.
Savaiano DA, Story JA. Cardiovascular Disease and Fiber: Is Insulin Resistance the Missing Link? Nutr. Rev. 2009;58:356–8.
Rader DJ. Effect of Insulin Resistance, Dyslipidemia, and Intra-abdominal Adiposity on the Development of Cardiovascular Disease and Diabetes Mellitus. Am. J. Med. 2007;120:S12–8.
Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development.
Nat. Rev. Endocrinol. 2014;10:293–302.
Reaven G. Insulin resistance and coronary heart disease in nondiabetic individuals. Arterioscler. Thromb. Vasc. Biol. 2012;32:1754–9.
Howard G, O’Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R et al. Insulin sensitivity and atherosclerosis. Circulation. 1996;93:1809–17.
Pyörälä M, Miettinen H, Laakso M, Pyörälä K. Hyperinsulinemia predicts coronary heart disease risk in healthy middle- aged men: The 22-year follow-up results of the Helsinki Policemen Study. Circulation. 1998;98:398–404.
Després JP, Lamarche B, Mauriège P, Cantin B, Dagenais GR, Moorjani S et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N. Engl. J. Med. 1996;334:952–7.
Eschwege E, Richard JL, Thibult N, Ducimetière P, Warnet JM, Claude JR et al. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study, ten years later. Horm. Metab. Res. Suppl. 1985;15:41–6.
Fontbonne AM, Eschwege EM. Insulin and Cardiovascular Disease: Paris Prospective Study. Diabetes Care. 1991;14:461–9.
Romańska R, Franek E. Współczesne leczenie otyłości u pacjentów z cukrzycą. Post N Med. 2017:89–94.
Turner R. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–65.
Fowler M. Leczenie cukrzycy: insulina i inkretyny. Diabetol. po Dyplomie. 2011;8:41–6.
Suliburska J, Kuśnierek J. Czynniki żywieniowe i pozażywieniowe w rozwoju insulinooporności. Forum Zaburzeń Metab. 2010;1:177–83.
Kowalska H, Lenart A, Marzec A, Kowalska J, Samborska K, Żebrowska MA. Wykorzystanie Produktów Prozdrowotnych I Suplementów Diety W Insulinoopornośći. Postępy Tech. Przetwórstwa Spożywczego. 2017;2:46–55.
Lee J, Sugiyama T, Liu Y, Wang J, Gu X, Lei J et al. Expansion and conversion of human pancreatic ductal cells into insulin-secreting endocrine cells. Elife. 2013. doi:10.7554/eLife.00940.
Zdrojewicz Z, Bugaj B, Cabała K, Pypno D, Waracki M. Nowoczesne kierunki leczenia cukrzycy. Diabetol. Klin. 2014;3:198–205.
Downloads
Published
How to Cite
Issue
Section
License
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 819
Number of citations: 0
